NCT06461533View on ClinicalTrials.gov

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

RecruitingOBSERVATIONAL

Enrollment

25

Participants

Timeline

Start Date

June 10, 2024

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions

Acquired Hemophilia A

Interventions

DRUG

Susoctocog Alfa (Genetical Recombination)

Susoctocog Alfa (Genetical Recombination), Intravenous injection

Trial Locations (1)

Unknown

RECRUITING

Takeda selected site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY

NCT06461533 - A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A | Biotech Hunter | Biotech Hunter